{'fraction_non_alphanumeric': 0.036805988771054274, 'fraction_numerical': 0.049282595134123516, 'mean_word_length': 5.030075187969925, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Identiﬁcation and Characterization of Glima 38, a Glycosylated Islet Cell Membrane Antigen, Which Together with GAD 65 and IA2 Marks the Early Phases of Autoimmune Response in Type 1 Diabetes

Immunoprecipitating IgG autoantibodies to glutamic acid decarboxylase, GAD 65 , and/or a tyrosine phosphatase, IA2, are present in the majority of individuals experiencing pancreatic (cid:98) cell destruction and development of type 1 diabetes. Here we identify a third islet cell autoantigen, a novel 38-kD protein, which is specifically immunoprecipitated with sera from a subset of prediabetic individuals and newly diagnosed type 1 diabetic patients. The 38-kD autoantigen, named glima 38, is an amphiphilic membrane glycoprotein, specifically expressed in islet and neuronal cell lines, and thus shares the neuroendocrine expression patterns of GAD 65 and IA2. Removal of N-linked carbohydrates results in a protein of 22,000 M r . Glima 38 autoantibodies were detected in 16/86 (19%) of newly diagnosed patients, including three very young children, who had a rapid onset of disease, and in 6/44 (14%) of prediabetic individuals up to several years before clinical onset. The cumulative incidence of GAD 65 and glima 38 antibodies in these two groups was 83 and 80%, respectively, and the cumulative incidence of GAD 65 , glima 38, and IA2 antibodies in the same groups was 91 and 84%, respectively. GAD 65 , IA2, and glima 38 represent three distinct targets of immunoprecipitating IgG autoantibodies associated with (cid:98) cell destruction and type 1 diabetes. ( J. Clin. Invest. 1996. 97:2772–2783.)